- Coordinates
- PDB Format
- Method
- ELECTRON MICROSCOPY
- Oligo State
- hetero-3-3-3-3-1-1-mer
- Ligands
- 3 x NAG- NAG- BMA- MAN- MAN- MAN: alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 3 x NAG- NAG- BMA- MAN: alpha-D-mannopyranose-(1-3)-beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
NAG-NAG-BMA-MAN.2: 11 residues within 4Å:- Chain C: S.179, E.181, P.182, V.224, L.231, N.232, N.346, G.348, V.414, S.415
- Ligands: NAG.18
2 PLIP interactions:2 interactions with chain C- Hydrogen bonds: C:S.179, C:G.348
- Hydrophobic interactions: C:V.414
NAG-NAG-BMA-MAN.5: 12 residues within 4Å:- Chain I: S.179, E.181, P.182, K.222, V.224, L.231, N.232, N.346, G.348, V.414, S.415
- Ligands: NAG.30
2 PLIP interactions:2 interactions with chain I- Hydrogen bonds: I:G.348, I:V.414
NAG-NAG-BMA-MAN.8: 11 residues within 4Å:- Chain M: S.179, P.182, V.224, L.231, N.232, N.346, G.348, C.413, V.414, S.415
- Ligands: NAG.42
2 PLIP interactions:2 interactions with chain M- Hydrogen bonds: M:G.348, M:V.414
- 3 x NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
NAG-NAG.3: 4 residues within 4Å:- Chain C: Q.332, T.341, T.342, N.355
1 PLIP interactions:1 interactions with chain C- Hydrogen bonds: C:Q.332
NAG-NAG.6: 5 residues within 4Å:- Chain I: Q.332, T.341, T.342, N.355, S.357
1 PLIP interactions:1 interactions with chain I- Hydrogen bonds: I:Q.332
NAG-NAG.9: 5 residues within 4Å:- Chain M: Q.332, T.341, T.342, N.355, S.357
1 PLIP interactions:1 interactions with chain M- Hydrogen bonds: M:Q.332
- 36 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
NAG.10: 4 residues within 4Å:- Chain C: E.57, N.58
- Chain D: G.13, S.17
Ligand excluded by PLIPNAG.11: 5 residues within 4Å:- Chain C: Y.104, N.118, Y.135, L.137, G.289
Ligand excluded by PLIPNAG.12: 4 residues within 4Å:- Chain C: Q.100, S.120, F.121, N.122
Ligand excluded by PLIPNAG.13: 4 residues within 4Å:- Chain C: V.144, R.162, N.167
- Chain I: R.278
Ligand excluded by PLIPNAG.14: 5 residues within 4Å:- Chain C: N.204, T.206, S.244, I.247, H.321
Ligand excluded by PLIPNAG.15: 3 residues within 4Å:- Chain C: N.246, T.248, N.249
Ligand excluded by PLIPNAG.16: 4 residues within 4Å:- Chain C: Q.263, N.265, S.303, R.412
Ligand excluded by PLIPNAG.17: 3 residues within 4Å:- Chain C: N.271, I.292, V.410
Ligand excluded by PLIPNAG.18: 5 residues within 4Å:- Chain C: N.232, P.261, V.414, N.416
- Ligands: NAG-NAG-BMA-MAN.2
Ligand excluded by PLIPNAG.19: 2 residues within 4Å:- Chain C: N.103, G.114
Ligand excluded by PLIPNAG.20: 1 residues within 4Å:- Chain D: N.100
Ligand excluded by PLIPNAG.21: 3 residues within 4Å:- Chain D: K.122, E.123, N.126
Ligand excluded by PLIPNAG.22: 5 residues within 4Å:- Chain I: E.57, N.58
- Chain J: L.9, G.13, S.17
Ligand excluded by PLIPNAG.23: 6 residues within 4Å:- Chain I: Y.104, N.118, Y.135, L.137, G.289, D.290
Ligand excluded by PLIPNAG.24: 5 residues within 4Å:- Chain I: Q.100, S.120, F.121, N.122, K.133
Ligand excluded by PLIPNAG.25: 3 residues within 4Å:- Chain I: V.144, R.162, N.167
Ligand excluded by PLIPNAG.26: 4 residues within 4Å:- Chain I: N.204, S.244, I.247, H.321
Ligand excluded by PLIPNAG.27: 3 residues within 4Å:- Chain I: N.246, T.248, N.249
Ligand excluded by PLIPNAG.28: 6 residues within 4Å:- Chain I: Q.263, N.265, N.301, S.303, R.412, V.414
Ligand excluded by PLIPNAG.29: 3 residues within 4Å:- Chain I: N.271, I.292, V.410
Ligand excluded by PLIPNAG.30: 5 residues within 4Å:- Chain I: N.232, P.261, V.414, N.416
- Ligands: NAG-NAG-BMA-MAN.5
Ligand excluded by PLIPNAG.31: 2 residues within 4Å:- Chain I: N.103, E.106
Ligand excluded by PLIPNAG.32: 2 residues within 4Å:- Chain J: N.100, S.102
Ligand excluded by PLIPNAG.33: 2 residues within 4Å:- Chain J: E.123, N.126
Ligand excluded by PLIPNAG.34: 5 residues within 4Å:- Chain M: E.57, N.58
- Chain N: L.9, G.13, S.17
Ligand excluded by PLIPNAG.35: 5 residues within 4Å:- Chain M: Y.104, N.118, Y.135, L.137, G.289
Ligand excluded by PLIPNAG.36: 4 residues within 4Å:- Chain M: Q.100, S.120, F.121, N.122
Ligand excluded by PLIPNAG.37: 3 residues within 4Å:- Chain M: V.144, R.162, N.167
Ligand excluded by PLIPNAG.38: 5 residues within 4Å:- Chain M: N.204, T.206, S.244, I.247, H.321
Ligand excluded by PLIPNAG.39: 3 residues within 4Å:- Chain M: N.246, T.248, N.249
Ligand excluded by PLIPNAG.40: 4 residues within 4Å:- Chain M: Q.263, N.265, N.301, S.303
Ligand excluded by PLIPNAG.41: 3 residues within 4Å:- Chain M: N.271, I.292, V.410
Ligand excluded by PLIPNAG.42: 6 residues within 4Å:- Chain M: N.232, L.235, P.261, V.414, N.416
- Ligands: NAG-NAG-BMA-MAN.8
Ligand excluded by PLIPNAG.43: 2 residues within 4Å:- Chain M: N.103, K.113
Ligand excluded by PLIPNAG.44: 1 residues within 4Å:- Chain N: N.100
Ligand excluded by PLIPNAG.45: 3 residues within 4Å:- Chain N: E.123, N.126, Y.127
Ligand excluded by PLIP- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Xie, Z. et al., mRNA-LNP HIV-1 trimer boosters elicit precursors to broad neutralizing antibodies. Science (2024)
- Release Date
- 2024-05-15
- Peptides
- RM20A3 Fab heavy chain: AEK
RM20A3 Fab light chain: BFL
Envelope glycoprotein gp120: CIM
Transmembrane protein gp41: DJN
B16_d77.5 mouse Fab heavy chain Fv: G
B16_d77.5 mouse Fab light chain Fv: H - SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
GE
CK
MB
IF
DL
NC
EI
AM
JD
FJ
BN
KG
HH
L
- Coordinates
- PDB Format
- Method
- ELECTRON MICROSCOPY
- Oligo State
- hetero-3-3-3-3-1-1-mer
- Ligands
- 3 x NAG- NAG- BMA- MAN- MAN- MAN: alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 3 x NAG- NAG- BMA- MAN: alpha-D-mannopyranose-(1-3)-beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 3 x NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 36 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Xie, Z. et al., mRNA-LNP HIV-1 trimer boosters elicit precursors to broad neutralizing antibodies. Science (2024)
- Release Date
- 2024-05-15
- Peptides
- RM20A3 Fab heavy chain: AEK
RM20A3 Fab light chain: BFL
Envelope glycoprotein gp120: CIM
Transmembrane protein gp41: DJN
B16_d77.5 mouse Fab heavy chain Fv: G
B16_d77.5 mouse Fab light chain Fv: H - SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
GE
CK
MB
IF
DL
NC
EI
AM
JD
FJ
BN
KG
HH
L